Test whether carefully titrated D2-pathway modulation can normalize pathological autoreceptor signaling after alpha-synuclein pathology is established. The current debate supports this only as a mechanistic probe with direct electrophysiology and dopamine-release readouts, not yet as a strong therapeutic program.
Restore RGS6 in substantia nigra pars compacta dopaminergic neurons after established alpha-synuclein pathology to test whether RGS6 loss is not only necessary but therapeutically reversible. The decisive experiment is delayed intervention in PFF or AAV-SNCA models with unbiased stereology, terminal preservation, dopamine physiology, and catalytically dead RGS6 controls.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Protein Aggregationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
2/11
dimensions won
Pharmacologic modulation of D2 autorecep
9/11
dimensions won
AAV-mediated RGS6 re-expression in SNpc
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.31
0.48
Evidence
0.29
0.42
Novelty
0.51
0.74
Feasibility
0.61
0.58
Impact
0.34
0.55
Druggability
0.57
0.62
Safety
0.27
0.28
Competition
0.46
0.63
Data
0.49
0.52
Reproducible
0.34
0.46
KG Connect
0.50
0.12
Score Breakdown
Dimension
Pharmacologic modulation of D2
AAV-mediated RGS6 re-expressio
Mechanistic
0.310
0.480
Evidence
0.290
0.420
Novelty
0.510
0.740
Feasibility
0.610
0.580
Impact
0.340
0.550
Druggability
0.570
0.620
Safety
0.270
0.280
Competition
0.460
0.630
Data
0.490
0.520
Reproducible
0.340
0.460
KG Connect
0.500
0.118
Evidence
Pharmacologic modulation of D2 autoreceptor-Gi/o signaling i
No evidence citations yet
AAV-mediated RGS6 re-expression in SNpc after pathology onse
No evidence citations yet
Debate Excerpts
Pharmacologic modulation of D2 autoreceptor-Gi/o s
4 rounds · quality: 0.54
Persona-Theorist
# Therapeutic Hypotheses: RGS6 Upregulation & D2 Autoreceptor Modulation in Established Parkinson's Models
---
## Hypothesis 1: AAV-Mediated RGS6 Overexpression in Substantia Nigra Rescues Establish...
Persona-Skeptic
Several of these hypotheses over-interpret a loss-of-function phenotype as if it implied therapeutic gain-of-function, and several supporting citations are mismatched to the claims. After checking the...
Persona-Domain Expert
# Feasibility Assessment: RGS6 and D2 Autoreceptor Modulation in Established PD Models
## Executive Summary
The SKEPTIC's analysis effectively deflates most of these hypotheses, leaving two core tes...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "AAV-mediated RGS6 re-expression in SNpc after pathology onset",
"description": "Restore RGS6 in substantia nigra pars compacta dopaminergic neuro...
AAV-mediated RGS6 re-expression in SNpc after path
4 rounds · quality: 0.54
Persona-Theorist
# Therapeutic Hypotheses: RGS6 Upregulation & D2 Autoreceptor Modulation in Established Parkinson's Models
---
## Hypothesis 1: AAV-Mediated RGS6 Overexpression in Substantia Nigra Rescues Establish...
Persona-Skeptic
Several of these hypotheses over-interpret a loss-of-function phenotype as if it implied therapeutic gain-of-function, and several supporting citations are mismatched to the claims. After checking the...
Persona-Domain Expert
# Feasibility Assessment: RGS6 and D2 Autoreceptor Modulation in Established PD Models
## Executive Summary
The SKEPTIC's analysis effectively deflates most of these hypotheses, leaving two core tes...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "AAV-mediated RGS6 re-expression in SNpc after pathology onset",
"description": "Restore RGS6 in substantia nigra pars compacta dopaminergic neuro...